A Systematic Review and Meta-analysis of Polycystic Ovary Syndrome and Mental Health among Black Asian Minority Ethnic populations

Authors

Gayathri DELANEROLLE,^{1*} Salma AYIS^{2*}, Vanya BARZILOVA^{3**}, Peter PHIRI,^{5,7**} Yutian ZENG^{9**}, Sandali RANAWEERA,^{6**} Ashish SHETTY^{3,4**}, Nyla HAQUE¹², Debasish KAR¹, Kingshuk MAJUMDER⁸, Shanaya RATHOD⁵, Vanessa RAYMONT,¹² Jian Qing SHI^{9,10***}, Dharani K. HAPANGAMA^{3,7***}

Affiliations

¹University of Oxford, Nuffield Department of Primary Health Care Sciences

²Kings College London

³University of Liverpool

⁴University College London Hospitals NHS Foundation Trust

⁵University College London

⁶Southern Health NHS Foundation Trust

⁷Liverpool Women's NHS Foundation Trust

⁸University of Southampton, School of Primary Care, Population Sciences and

Medical Education, Faculty of Medicine

⁹University of Manchester NHS Foundation Trust

¹⁰Southern University of Science and Technology

¹¹Alan Turing Institute

¹²Department of Psychiatry, University of Oxford

Shared first authorship*

26 Shared second authorship**

27 Shared last authorship***

28

29

30 **Conflicts of Interest**

31 PP has received research grant from Novo Nordisk, and other, educational from
32 Queen Mary University of London, other from John Wiley & Sons, other from Otsuka,
33 outside the submitted work.

34

35 SR reports research funding associated with other studies from Janssen, Otsuka and
36 Lundbeck.

37

38 GD reports grants from the NIHR and GSK, which have been received for studies
39 external to the ELEMI project.

40

41 DKH reports grants from MRC, Wellbeing for women, which has been received for
42 studies external to the ELEMI project.

43

44 The views expressed are those of the authors and not necessarily those of the NHS,
45 the National Institute for Health Research, the Department of Health and Social Care
46 or the Academic institutions.

47

48

49 **PROSPERO registration number:** CRD42020210863

50

51

52 **Correspondence to:** dharani@liv.ac.uk

53 Professor Dharani K. Hapangama

54 Department of Women's and Children's Health,

55 Institute of Life Course and Medical Sciences,

56 University of Liverpool

57 Liverpool Women's Hospital NHS Trust

58 Crown Street, Liverpool L8 7SS, United Kingdom

59

60

61

62

63

64

65

66

67

68

69

70

71

72 **Word count (abstract): X**

73 **Word count (main text): X**

74

75

76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118

Abstract

119

120 **Background:** Polycystic Ovary Syndrome (PCOS) is a chronic and a common
121 gynaecological condition impacting women of reproductive age. Women with PCOS

have hormonal, ovulatory and metabolic dysfunction resulting in multiple symptoms. The correlation between hormonal disbalance and the impact on women's mental health (MH) has been researched for decades. However, the prevalence among different ethnicities has not been fully evaluated.

Methods: A systematic methodology was developed, and a protocol was published in PROSPERO (CRD42020210863) and a systematic review of publications between 1st January 1990- 30th January 2021 was conducted. Multiple electronic databases were explored using keywords and MeSH terms. The finalised dataset was analysed using statistical methods such as random-effect models, subgroup analysis and sensitivity analysis.

Findings: We included 30 studies reporting on 3,944 PCOS women. Majority of studies addressed depression anxiety, and common mental health. Studies had fair to poor methodological quality and includes observational studies and Randomised Clinical Trials (RCTs). Overall, 17% (95% CI: 7% to 29%) of women with PCOS have clinical diagnosis of major or severe depression; 33% (95% CI: 26% to 40%) have elevated depressive symptoms or a clinical diagnosis of depression; 41% (95% CI: 28% to 54%) report anxiety symptoms, and 31% (95% CI: 15% to 51%) have a form a common mental health or are taking psychiatric medication for anxiety and / or depression. The use of various tools to assess mental health symptoms was among the reasons for the substantial heterogeneity across studies.

Interpretation:

PCOS is associated with an increased risk of mental health disorders including depressive s, anxiety, and other mental health disorders. While BAME populations account for about 20% of most of the samples studied, stratification by ethnicity was rarely attempted which made it difficult to elucidate the MH impact of PCOS on different communities.

Funding: Not applicable

Keywords: Polycystic Ovary Syndrome, PCOS, BAME, Mental Health, Women's Health and Wellbeing

Introduction

Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in women of reproductive age with significant reproductive, metabolic, and psychological implications. An estimated 8-13% of women of reproductive age are

affected,¹⁻⁵ with a widely quoted similar prevalence between different ethnicities.⁶

The Rotterdam criteria,^{5,7} which incorporates a combination of signs and symptoms of androgen excess, ovarian dysfunction and polycystic ovarian morphology on ultrasound is the globally accepted diagnostic criteria for PCOS. The phenotype between different ethnicities, can vary markedly^{5,8,9} with PCOS sufferers from Hispanic, East Asian, South Asian and Middle Eastern backgrounds displaying higher prevalence of symptoms associated with hyperandrogenism^{8,9} than their White counterparts. The precise aetiology of the syndrome is unclear, although evidence suggests a genetic predisposition, and a role of environmental variables including diet and lifestyle factors.^{10,11} The pathophysiology involves a dysfunctional hypothalamic-pituitary-ovarian axis, with inappropriate gonadotropin-releasing hormone (GnRH) pulsatility and increased pituitary secretion of luteinizing hormone (LH).¹² Those affected with PCOS present with a wide spectrum of clinical symptoms and features, which can be reproductive (oligomenorrhoea, hirsutism, subfertility), metabolic^{13,14} (insulin resistance, type 2 diabetes, metabolic syndrome), and psychological^{15,16} (depression, anxiety and low quality of life).

PCOS, due to its diversity in clinical presentation, remains undiagnosed in up to 70% of women,³ this may lead to various clinical sequelae that impact and complicate women's long-term health. For example women with PCOS have an increased risk of consequential complications such as type 2 diabetes mellitus, cardiovascular disease, endometrial cancer, pregnancy complications and psychological conditions.¹⁷⁻²⁰

One area lacking in PCOS research are the MH correlates of the syndrome. The limited evidence available suggests that women with PCOS have higher rates of

depression, anxiety, binge eating disorders, bipolar disorder and other psychological symptoms,²¹⁻²³ most likely due to the androgenic, reproductive, and metabolic disorders or due to the associated symptoms of the disorder.^{24,25} Current treatment for PCOS focuses on physical symptom control and reducing complication rates.²⁶ At a global level, currently, there is limited recognition of mental health (MH) symptoms in women with PCOS.⁵ However, background MH sequelae may significantly impact treatment adherence and patient quality of life.⁵

MH disorders account for 14% of global burden of disease.²⁷ Yet significant disparities persist in providing access to MH services for Black, Asian and Minority Ethnic (BAME) populations.²⁸ This is further exacerbated by the underreporting of MH symptoms in BAME individuals who are less likely to contact their general practitioner regarding their MH compared to their White British counterparts.²⁸ This can be explained by a combination of personal and environmental factors, including inability to recognise MH symptoms, cultural identity and stigma, language barrier and poor communication with healthcare professionals.²⁸ Therefore, the prevalence of MH disturbances in BAME women with PCOS remains unclear. The MH symptom prevalence rates may differ significantly across races and ethnicities for women with PCOS in the form of either symptoms and/or psychiatric disorders. Understanding the multifactorial and heterogenic nature of PCOS presentation in BAME women is crucial to improve clinical and patient reported outcomes.

An assessment of the existing evidence is vital to generate comprehensive knowledge and clinical practice improvements that are suitable for BAME

populations. Therefore, a systematic review was designed and developed within this study.

Methods

A systematic methodology was developed and peer reviewed prior to publication in PROSPERO in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA).

Research question

To assess the prevalence of the disease sequelae between PCOS and mental health symptoms and disorders among BAME populations.

Search Strategy

The search strategy involved multiple databases of EMBASE, PubMed, PsycINFO, Science direct and Web of Science from inception to the 30th of May 2021. The searches were conducted through references initially followed by the review al their abstracts and tracking of citations.

Eligibility criteria

All peer review publications in English were included to this study. Key words and MeSH terms included *depression, polycystic ovary syndrome, PCOS, bipolar, dysthymia, major depressive disorder, anxiety, psychosis, somatic symptoms,*

psychotic disorders, trauma, stress, post traumatic stress (PTSD), obsessive-compulsive spectrum disorders, ethnic minorities, BAME, BME and eating disorders.

Studies that included a psychiatric diagnosis or MH symptomatologies based on a clinically structured diagnostic interview and/or clinically accepted screening tools were eligible for this study. Meeting abstracts were excluded if there was no full paper available.

Data extraction and analysis

Predefined clinical variables were used as part of the data extraction of rates of depression, anxiety, stress, schizophrenia, psychosis and PTSD within the search strategy. An evidence synthesis methods protocol was developed and has been shown as supplementary document 1. The data extraction process was completed as per the PRISMA guidelines whilst, the refinement protocol has been shown in the supplementary document 1. The extracted data was reviewed using Endnote and Microsoft Excel by 3 reviewers prior to the statistical analysis. All studies collated were categorised based on MH symptoms versus psychiatric disorders and, where possible synthesised based on prevalence and 95% confidence intervals. Prevalence tables were developed to indicate any subgroup categories including geographical location, race, heterogeneity, age, obesity scores and ethnicity. Systematically included studies that did not meet the meta-analysis criteria due to insufficient statistical data or poor quality were narratively synthesised and analysed based on the disease, family, clinician and patient perspective. The narration would include the reporting of common themes including potential barriers to identify and report any themes or sub-themes that may be present in clinical guidelines.

286

287

288

289 *Outcomes*

290 The primary outcome was to assess the odds ratios and p-values associated with a
291 possible mental health symptomatology and/or psychiatric disorders among PCOS
292 BAME populations.

293

294 *Statistical analysis plan*

295 Depression was measured by a range of scales and several tools including the
296 Diagnostic and Statistical Manual of Mental Disorders (DSM)²⁹; the Patient Health
297 Questionnaire (PHQ)³⁰; the Hospital Anxiety and Depression (HAD)³¹; Beck
298 Depression Inventory (BDI)³²; Montgomery Åsberg Depression Rating Scale
299 (MADRS-S)³³; Center for Epidemiologic Studies Depression (CES-D)³⁴; Reynolds
300 Adolescent Depression Scale, 2nd Edition (RADSD-2)³⁵; Quick Inventory Depressive
301 Symptomatology (QIDS)³⁶; Self-Reported Questionnaire Scale-20 (SRQ-20)³⁷; the
302 Generalized Anxiety Disorder (GAD)³⁸; the International Neuropsychiatric Interview
303 (MINI),³⁹ use of antidepressants or use of anti-anxiety medication; a diagnosis by a
304 MH professional, and self-reported history of depression.

305

The types of mental illness considered by most studies were anxiety, depression, both anxiety and depression, and generalised mental wellbeing. The prevalence of these was synthesised using a meta-analysis.

For the purpose of this study, depression was defined as a major depression diagnosis or elevated depressive symptoms, as reported within the systematically included studies. The diagnosis of major depressive disorder (MDD) was based on clinical review which included suicidal ideations, or provided a definition of MDD based on thresholds of tools used, for example, BDI ≥ 17 , CES-D ≥ 24 .^{40,41} Elevated depression included clinical depression, antidepressants use, and / or a threshold for mild to moderate depression based on the scale used for assessment, for example BDI ≥ 11 , HAD-D ≥ 8 , and CES-D ≥ 16 . For anxiety, a combinational approach was used where the use of the term anxiety or use of anxiety medications were pooled together, due to overlapping definitions, and lack of clear cuts for severity levels. Generalised mental wellbeing on the other hand was defined, as having both depression and anxiety, use of medication for psychiatric disorders as reported within the studies, self-reported MH symptoms, or reported under the term “common mental health” (CMH) by a study authors based on scales such as SF-36.⁴²⁻⁴⁴

A Random-effects models were used to calculate overall summary estimates of anxiety, depression, and CMH in PCOS patients.⁴⁵ The routine “metaprop” of the software STATA’s (V.16) which provides pooled summary of proportions and 95% confidence intervals based on Newcombe exact binomial estimation was used.^{46,47} The routine also estimates the I-squared statistics which describes the percentage of

variation across studies that is due to heterogeneity rather than chance. (Higgins et al. 2003)⁴⁸

All studies systematically included demonstrate a range of study designs including of observational and randomised clinical trials (RCTs). Where comparisons were made between PCOS and non-CPOS groups in a study, only the PCOS groups were included. At situations where PCOS population were stratified by certain criterion, for example body mass Index (BMI) or age, the strata were combined where the sample size was smaller than 30 for each group, and an overall prevalence was calculated. For larger groups, each was treated a separate group. Sensitivity analyses in addition, were used to highlight differences across strata where a criterion proven to have an impact on heterogeneity.

Publication bias was assessed using funnel plots and Egger test, for symmetry and small study effects where the number of studies exceeded the recommended 10.^{49,50}

Risk of Bias (Quality assessment)

The Newcastle-Ottawa-Scale (NOS) was used to assess the risk of bias (RoB) for all systematically included studies as demonstrated within the RoB table.

Sensitivity analysis

Sensitivity analysis was used to explore causes of heterogeneity. BMI, and tool of assessment of assessments were used for stratification.

Results

Figure 1 displays the estimated prevalence and 95% confidence intervals (CI) for the mental health conditions classified as: (a) Major depressive disorder, (b) Elevated existing depression, (c) Anxiety and (d) Common mental health.

Overall, major depressive disorder affected 17% of PCOS patients, and vary between 0% to 67%. All studies except two have estimated a prevalence $\geq 10\%$. The highest prevalence was reported in a Swedish study, followed by two Middle Eastern (ME) studies, with a prevalence of 67%, 29%, and 22% for the three studies respectively.⁵¹⁻⁵³ Substantial heterogeneity, I^2 of 93.98% was reported between regions, also considerably high within USA studies, I^2 of 71.33% but the two ME studies were homogeneous, Figure 1 (a).

Depression was summarised from 24 studies, including 3157 women with PCOS. The estimated average was 33% (95% CI: 26% to 40%). Where the estimated prevalence was stratified by region, fairly similar estimates on average, were noted across regions, with India being the only exception where the highest prevalence of 64% (95% CI: 55% to 73%) was reported. Substantial heterogeneity observed within regions and between regions. The overall heterogeneity was 93.24%.

For anxiety, Figure 1 (C), the highest prevalence of 75% was seen in a USA study, with 78% white and 22% non-white, mean age 33 years (SD: 7.5), followed by a prevalence of 74% in a European study with 80% white, 18% Asian, age 33 years (7.4), while the two studies didn't report BMI.^{54,55} Middle East, and Australia/ NZ

follow with an estimated averages of 42% and 38% respectively, and the overall estimated prevalence was 41% (95% CI: 28% to 54%).

Figure 1 (d), common mental health overall prevalence was 31% (95% CI: 15% to 51%). Substantial heterogeneity shown by USA studies, only one study from ME, and one from Brazil were included. A substantial lack of consistency across studies was reflected by a heterogeneity I^2 of 97.29%.

Figure 1. The Prevalence of Mental Health Indicators in Women with PCOS

(a) Major depression by region

Supplementary a1: Major depression by BMI (sensitivity)

396
397

398

399 Supplementary a2: Major depression by assessment tool (sensitivity)

QIDS: Quick Inventory of Depressive Symptomatology-Self Report 16,¹

MINI: MINI International Neuropsychiatric Interview,³

(b) Elevated depression by region

Supplementary b1: elevated depression by BMI (sensitivity)

Supplementary b2: elevated depression by assessment tool (sensitivity)

(c) Prevalence of anxiety by region

Supplementary c1: Prevalence of anxiety by BMI (sensitivity)

Supplementary c2: Prevalence of Anxiety by assessment tool (sensitivity)

451

452

453

454

455

456

457

458

459

460

(d) Common mental health by region

Supplementary d1: Common mental health by BMI (sensitivity)

Supplementary d: Common mental health by assessment tool (sensitivity)

471

472 SRQ SCALE-20: Self-reported questionnaire scale-20, 2

FIGURE 2.

(a) Funnel Plot (Prevalence of elevated depression)

Note. The figure visually supports an asymmetrical shaped funnel plot. The no small study effect null hypothesis (H_0 : no small-study effect) may therefore be rejected. Using Egger test of H_0 : no small-study effects, p value = 0.004.

(b) Funnel Plot (Prevalence of anxiety)

(c)

Note. The figure visually supports the symmetry of the effect size distribution. The correlation between effect size and the corresponding standard error was not strong, Egger's test p value = 0.65 supporting no small-study effect (symmetry) hypothesis.

Discussion

The meta-analysis identified 11 studies which reported a 20% prevalence of common MH symptoms of anxiety and depression primarily. However, there was substantial heterogeneity across all studies which is reflected by I^2 of 97.29%. Sources contributing to this heterogeneity may include differences in age range, body mass index (BMI), region, study design (including psychiatric assessments

used), sample size and methodology, population ethnicity and other characteristics. The narrative synthesis identified several key themes including symptoms of depression and anxiety, as well as diagnosed conditions of eating disorders, bipolar disorder, PTSD and psychotic disorders as demonstrated in **Table x**.

Despite being the most common reproductive endocrine disorder that spans through the entire reproductive life of a woman, PCOS is often associated with a significant negative patient experience, including delayed diagnosis, that could attribute to exacerbation of symptoms.⁵⁶⁻⁵⁸ Due to the chronic nature of the disease, challenges with persistent treatment adherence is a common issue, but lifestyle changes can be useful to decrease the long-term consequences of the disease. However, once diagnosed, only 19% of women report being aware of all conditions associated with PCOS following discussions with their general practitioner (GP).⁵⁹ The typical symptoms of PCOS such as disturbed menstrual cycles, hirsutism, male-pattern baldness, acne, obesity, and infertility^{12,60-63} could have a further negative impact on patient self-esteem leading to psychological burden. However, narrative accounts point to considerable emphasis on a few symptoms such as infertility by the clinicians, rather than taking a holistic view on all important features of the condition,⁵⁹ such as the long term physical and mental health sequelae, and the effect of diagnosis and treatments on quality of life of the woman. PCOS is also associated with a higher rate of psychiatric disorders.⁵⁶ In keeping with this, our meta-analysis reported 31% prevalence of common MH symptoms and diagnoses in women with PCOS. Similarly, Hillman et al. found an overwhelming 74.9% of women diagnosed with PCOS in their study, to have reported that the condition has adversely affected their MH.⁵⁹ However, despite the considerable negative effect on

psychological wellbeing, as many as 34.9% of women in the study chose not to discuss associated MH symptoms with their GP.⁵⁹ An important factor contributing to this may be the ethnic background of the patient. Hillman et al. report that caucasian women in UK diagnosed with PCOS were more likely to discuss their MH with their GP when compared with asian women in UK with PCOS (odds ratio [OR] = 1.66; 95% confidence interval [CI] = 1.04 to 2.63).⁵⁹ Clinicians and healthcare providers should better evaluate the needs of BAME communities. This would allow personalised care to be delivered in a culturally sensitive way, which may improve overall patient and clinical outcomes.

Around 1 in 6 adults in England meet the diagnostic criteria for common MH disorders.⁶⁴ BAME ethnic groups are more likely to be detained under the Mental Health Act compared to their White British counterparts, and this can be explained by higher rates of mental illness observed and poorer levels of support.⁶⁵ Several studies have explored beliefs about mental illness within BAME communities, and the barriers faced when accessing care. Factors which account for poor presentation rates with mental illness amongst the BAME community include associated stigma, including those with PCOS, poor English language skills, previous negative experiences with healthcare professionals, and being aware of available services.⁶⁶

The MH of patients with PCOS may be severely impacted by these issues and reluctance to seek help may further exacerbate pre-existing psychiatric conditions, or limit the recognition of new MH symptoms. Therefore, a thorough assessment of MH illness risk is particularly important in BAME women with PCOS. In agreement, the Royal College of Obstetricians and Gynaecologists (RCOG) recommends the routine screening for psychological symptoms in all women with PCOS.⁶⁷ Yet, our meta-analysis depicts that there is limited number of studies exploring psychological

comorbidities in PCOS patients, both in UK and worldwide. Additionally, our meta-analysis was unable to meet most pre-planned outcomes, including the effects of ethnicity and race on MH sequelae in PCOS women, due to the lack of data identified within systematically pooled studies. This was largely due to the non-reporting of patient race and ethnicity in PCOS studies examining patient MH.

The two most identified MH conditions amongst PCOS patients in our systematic review were depression and anxiety. Indeed, several existing studies comment on the high risk of both existing and new diagnoses of depression in women with PCOS.^{68,69} Our meta-analysis confirmed these findings, as major depression affected 17% of PCOS patients, and elevated existing depression affected 33%, with a considerably high heterogeneity in both subthemes within and between regions. Existing literature in the field measuring true prevalence of depression in BAME patients with PCOS is contradictory. This meta-analysis could not pool race or ethnicity with the data due to differences in research study designs and clinical practices, as well as the lack of BAME patient representation within studies. Therefore, the true prevalence of elevated existing depression and newly diagnosed major depression amongst BAME PCOS women could not be estimated. However, our narrative synthesis identified certain races/ethnicities to carry higher rates of depression than Caucasian PCOS patients.

Anxiety disorders include generalised anxiety disorder, panic disorder, separation anxiety disorder, social anxiety disorder and specific phobias⁷⁰ and may impair daily functioning. Women are twice as likely to develop anxiety disorders than men,⁷⁰ with women with PCOS have a significantly higher prevalence of generalised anxiety symptoms than women without PCOS.⁷¹ This study revealed that there are a small

number of published studies commenting on anxiety prevalence in women with PCOS. Of these, we identified 41% prevalence of generalised anxiety disorder among women with PCOS, however, heterogeneity was high at 94.83%. This heterogeneity extended to results from different regions suggests lack of difference between geographical locations in prevalence of anxiety amongst women with PCOS. Similar to our depression subtheme analysis, we were unable to establish the prevalence of anxiety amongst different ethnicities and races in women with PCOS due to lack of robust data.

Eating Disorders (EDs) have high prevalence particularly in young women worldwide.⁷² Body image disturbances and self-esteem are central to the development of common EDs and conditions that may affect body image has been found to contribute to the development of EDs.⁷³ The body dissatisfaction associated with features such as weight gain, hyperandrogenism, hirsutism, acne, and androgenic alopecia often contribute to disturbed body image perception linked with EDs. Existing literature, although informative on the relationship between PCOS and EDs, struggles to report findings on ethnic differences in ED and PCOS. Only two observational studies were identified addressing EDs in BAME PCOS patients,^{74,75} and although they report an increased risk of disordered eating habits in PCOS women compared with the control populations, in agreement, one study found Black, Hispanic and Mixed race women with PCOS to have higher EDE-Q scores (a self-rating questionnaire of the range and severity of ED features) compared with White women⁷⁵ yet the other reported EDs to be similar in the BAME PCOS population.⁷⁵ However, discordant methodology and the use of external cohorts from a different country, makes the available evidence to be substandard to draw firm conclusions

on the specific prevalence of EDs in BAME women with PCOS, indicating the need for further research to understanding ethnic differences in PCOS and associated EDs.

Psychotic disorders, such as schizophrenia have been reported to be significantly more prevalent in patients with PCOS in a national study in Sweden.⁷⁶ However, there is a dearth of studies investigating the associations between conditions. Although people from BAME background had been reported to experience a higher prevalence rate of psychosis⁷⁷ compared to the Caucasian population in UK, only one cohort study explored the prevalence of psychotic disorders in Taiwanese PCOS patients,⁷⁸ and reported no statistical difference in prevalence of schizophrenia between the two populations.⁷⁸ This highlights the need for future high quality studies to assess psychotic illnesses relevant to PCOS amongst different ethnicities.

Bipolar disorder (BD) has been reported to be more prevalent in women with PCOS⁷⁹ compared to the general population and since it carries a 12-fold increased risk of suicide,⁸⁰ it is especially important to examine any causative common mechanistic relations between the two conditions. However, there is a caveat, in that there is a reported high prevalence of menstrual disorders in women receiving treatment for BD.⁸¹ Therefore, accounting for confounding variables such as medication and pre-existing conditions is vital in studies that assess prevalence of MH sequelae, such as BD, in BAME PCOS women. A study from Kashmir Valley⁸² reported BD rates of 2.72% compared to 0.00% in control participants while a nationwide cohort study from Taiwan⁷⁸ found no significant alteration in prevalence of BD in PCOS women compared to a control population. Further research is thus

required in order to develop understanding of the prevalence in different populations, as associations cannot be drawn with the limited data available.

This systematic review had further revealed the heterogeneity of diagnosing psychiatric disorders. Clinicians have adopted 8 different self-report questionnaires in their methodologies highlighted by this review. This limits our study's generalisability as well as any estimate of prevalence of a given psychiatric disorder.

Overall, although most studies used Rotterdam Criteria in the diagnosis of PCOS,⁵ 4 studies adopted the National Institutes of Health Criteria, 1990 to diagnose PCOS, which will bring obvious diagnostic bias.⁸³⁻⁸⁶ Future studies should strive to adapt internationally accepted, standardised criteria for the diagnosis of both PCOS and MH disorder to avoid sampling bias.

Medical practitioners may not be aware of the impact different cultures may have on patient's reporting of both physical and psychiatric symptoms. In general, members of BAME communities are less likely to engage with MH services or seek help before symptoms severely impact their function.^{87,88} Simkhada et al. found that members of Nepali and Iranian communities report improved MH care and support by healthcare professionals who were trained on different cultural practices.⁸⁹ Furthermore, clinicians in the study stated that a better understanding of different cultures to be beneficial for providing a culturally sensitive service. Therefore, training healthcare professionals in cultural norms within BAME communities is vital to better understand their knowledge and beliefs of MH symptoms, thereby allowing clinicians to provide a holistic, effective treatment approach when working with diverse

populations. Cultural competency training may also increase patient trust in clinicians and lead to early discussions of how PCOS may be affecting patients psychosocially within distinct BAME communities. This will therefore aid in early detection and effective and lasting treatment of MH sequelae of PCOS and personalise patient clinical care.

Limitations

Several limitations affected our systematic review and meta-analysis findings. Whilst studies listed often identified severe emotional distress amongst PCOS women, some of this was self-reported and therefore subjective, without the presence of a clinical diagnosis. This may mask the true prevalence of common MH conditions, such as depression and anxiety, amongst women with PCOS. A further limitation includes the high heterogeneity observed across all subtheme meta-analyses. Several sources of heterogeneity were behind the variations across estimates. These include the range of scales used, the choice of threshold, although many are equivalent but nonetheless, some disagreement remains and contributes to variations. Other factors such as differences in age range, body mass index (BMI), region, study design, sample size and methodology, population ethnicity and other characteristics, and the established unobserved heterogeneity, all tapping into the differences observed across studies.

The cultural differences in reporting MH symptoms across different regions, potentially further impacted by complex interaction with stigma and accepted norms within BAME communities may have specific effects on different populations. Moreover, the difference in reporting MH symptoms and diagnoses is a further limitation of all studies included in this review. Several diverse assessment tools

were used in the assessment of risk of key psychiatric disorders, including self-reported symptoms, self-reported use of psychiatric medication and clinical diagnosis, thereby introducing heterogeneity in studies included in this review. This may limit the generalisability of the data obtained, may mask the true prevalence of a given psychiatric disorder due to questionnaires' tendency to screen rather than diagnose.

Conclusion

This study demonstrates the lack of ethnic minority representation in research studies conducted among PCOS patients exploring a possible MH sequelae. To determine if there is a bi-directional relationship between PCOS and MH conditions among ethnic minorities, comprehensive research studies should be designed and conducted as part of a global initiative. A key attribute to the changing needs within women's physical and MH is the migratory patterns that changes the regional and global population. The associated nuances influence both clinical practice and the access to the health-care system, and therefore, regular, and careful scrutiny of contemporary evidence is essential to optimise the overall clinical care offered to these patients. As a result, cultural appropriation based training should be made available and accessible to healthcare professionals within primary and secondary care settings.

Data sharing statement

All data used within this study has been publicly available. The authors will consider the sharing the dataset gathered upon request.

Contributors

GD and DKH developed the systematic review protocol and embedded this within the ELEMI project's evidence synthesis phase. GD, VB, DKH, SR, + SA wrote the first draft of the manuscript. This was furthered by PP, AS, WG, NT, YZ, JS and SR. KM, GD, YZ, VB and JS shared database searches, study selection and extraction for analysis. SA and GD conducted the analysis including the design of the statistical analysis plan. GD, YZ, DKH, PP, KE, WG, NT, YZ, JS, KM, VR, AS, PB, HM, AM, WG and KM critically appraised and finalised the manuscript. All authors approved the final version of the manuscript.

Acknowledgements

The authors acknowledge support from Southern Health NHS Foundation Trust, and Liverpool Women's hospital. We would like to acknowledge Mrs Nyla Haque who inspired the discussion of BAME groups within the context of this study.

This paper is part of the multifaceted ELEMI project that is sponsored by Southern Health NHS Foundation Trust and in collaboration with the University of Liverpool, University College London, University College London NHS Foundation Trust, Liverpool Women's Hospital, Robinson Research Institute (University of Adelaide),

725 Ramaiah Memorial Hospital (India), University of Geneva and Manchester University

726 NHS Foundation Trust.

727

728 **Supplementary Materials**

729 All supplementary materials associated with this article can be found in the attached

730 Appendices.

731

References

- Abu Hashim H. Twenty years of ovulation induction with metformin for PCOS; what is the best available evidence?. *Reprod Biomed Online*. 2016;32(1):44-53. doi:10.1016/j.rbmo.2015.09.015
- Bjonnes AC, Saxena R, Welt CK. Relationship between polycystic ovary syndrome and ancestry in European Americans. *Fertil Steril*. 2016;106(7):1772-1777. doi:10.1016/j.fertnstert.2016.08.033
- Ding T, Hardiman PJ, Petersen I, Wang FF, Qu F, Baio G. The prevalence of polycystic ovary syndrome in reproductive-aged women of different ethnicity: a systematic review and meta-analysis. *Oncotarget*. 2017;8(56):96351-96358. doi:10.18632/oncotarget.19180
- Gibson-Helm M, Teede H, Dunaif A, Dokras A. Delayed Diagnosis and a Lack of Information Associated With Dissatisfaction in Women With Polycystic Ovary Syndrome. *J Clin Endocrinol Metab*. 2017;102(2):604-612. doi:10.1210/jc.2016-2963
- Greenhill C. Mechanism underlying beneficial effects of exercise in PCOS identified. *Nat Rev Endocrinol*. 2018;14(8):441. doi:10.1038/s41574-018-0041-1
- Koch L. Androgens inversely related to depression in PCOS. *Nat Rev Endocrinol*. 2011;7:438. doi:10.1038/nrendo.2011.97

Tzalazidis R, Oinonen KA. Continuum of Symptoms in Polycystic Ovary Syndrome (PCOS): Links with Sexual Behavior and Unrestricted Sociosexuality. *J Sex Res.* 2020;1-13.

Yildizhan R, Gokce AI, Yildizhan B, Cim N. Comparison of the effects of chlormadinone acetate versus drospirenone containing oral contraceptives on metabolic and hormonal parameters in women with PCOS for a period of two-year follow-up. *Gynecol Endocrinol.* 2015;31(5):396-400. doi:10.3109/09513590.2015.1006187

The Lancet Diabetes Endocrinology. Empowering women with PCOS. *Lancet Diabetes Endocrinol.* 2019;7(10):737. doi:10.1016/S2213-8587(19)30289-X

References

1. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W. Position statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. *J Clin Endocrinol Metab*. 2006;91(11):4237-4245. doi:10.1210/jc.2006-0178
2. Diamanti-Kandarakis E, Kandarakis H, Legro RS. The role of genes and environment in the etiology of PCOS. *Endocrine*. 2006;30(1):19-26. doi:10.1385/ENDO:30:1:19
3. March WA, Moore VM, Willson KJ, Phillips DI, Norman RJ, Davies MJ. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. *Hum Reprod*. 2010;25(2):544-551. doi:10.1093/humrep/dep399
4. Bozdag G, Mumusoglu S, Zengin D, Karabulut E, Yildiz BO. The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. *Human Reprod*. 2016;31(12):2841-2855. doi:10.1093/humrep/dew218
5. Teede H, Misso M, Costello M, et al. International evidence-based guideline for the assessment and management of polycystic ovary syndrome (PCOS). European Society of Human Reproduction and Embryology. 2018. <https://www.eshre.eu/Guidelines-and-Legal/Guidelines/Polycystic-Ovary-Syndrome>

-
- 805 6. Wolf WM, Wattick RA, Kinkade ON, Olfert MD. Geographical Prevalence of
806 Polycystic Ovary Syndrome as Determined by Region and Race/Ethnicity. *Int*
807 *J Environ Res Public Health*. 2018;15(11):2589. doi:10.3390/ijerph15112589
 - 808 7. The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group.
809 Revised 2003 consensus on diagnostic criteria and long-term health risks
810 related to polycystic ovary syndrome. *Fertil Steril*. 2004;81(1):19-25.
811 doi:10.1016/j.fertnstert.2003.10.004
 - 812 8. Sendur SN, Yildiz BO. Influence of ethnicity on different aspects of polycystic
813 ovary syndrome: a systematic review. *Reprod BioMed Online*.
814 2021;42(4):799-818. doi: 10.1016/j.rbmo.2020.12.006
 - 815 9. Engmann L, Jin S, Sun F, et al. Racial and ethnic differences in the polycystic
816 ovary syndrome metabolic phenotype. *Am J Obstet Gynecol*.
817 2017;216(5):493.e1-493.e13. doi:10.1016/j.ajog.2017.01.003
 - 818 10. Escobar-Morreale HF. Polycystic ovary syndrome: definition, aetiology, diagnosis
819 and treatment. *Nat Rev Endocrinol*. 2018;14(5):270-284.
820 doi:10.1038/nrendo.2018.24
 - 821 11. Amato P, Simpson JL. The genetics of polycystic ovary syndrome. *Best Pract*
822 *Res Clin Obstet Gynaecol*. 2004;18(5):707-718.
823 doi:10.1016/j.bpobgyn.2004.05.002
 - 824 12. Azziz R, Carmina E, Chen Z, et al. Polycystic ovary syndrome. *Nat Rev Dis*
825 *Primers*. 2016;2:16057. doi:10.1038/nrdp.2016.57
 - 826 13. Apridonidze T, Essah PA, Iuorno MJ, Nestler JE. Prevalence and characteristics
827 of the metabolic syndrome in women with polycystic ovary syndrome. *J Clin*
828 *Endocrinol Metab*. 2005;90(4):1929-1935. doi:10.1210/jc.2004-1045

-
- 829 14. Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of
830 risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic
831 ovary syndrome: a prospective, controlled study in 254 affected women. *J Clin*
832 *Endocrinol Metab.* 1999;84(1):165-169. doi:10.1210/jcem.84.1.5393
 - 833 15. Teede H, Deeks A, Moran L. Polycystic ovary syndrome: a complex condition
834 with psychological, reproductive and metabolic manifestations that impacts on
835 health across the lifespan. *BMC Medicine.* 2010;8(41):1-10.
836 doi:10.1186/1741-7015-8-41
 - 837 16. Moran L, Gibson-Helm M, Teede H, Deeks A. Polycystic ovary syndrome: a
838 biopsychosocial understanding in young women to improve knowledge and
839 treatment options. *J Psychosom Obstet Gynecol.* 2010;31(1):24-31.
840 doi:10.3109/01674820903477593
 - 841 17. Hillman SC, Bryce C, Caleyachetty R, Dale J. Women's experiences of diagnosis
842 and management of polycystic ovary syndrome: a mixed-methods study in
843 general practice. *Br J Gen Pract.* 2020;70(694):e322-e329.
844 doi:10.3399/bjgp20X708881
 - 845 18. Dokras A, Stener-Victorin E, Yildiz BO, et al. Androgen excess — Polycystic
846 Ovary Syndrome Society: position statement on depression, anxiety, quality of
847 life, and eating disorders in polycystic ovary syndrome. *Fertil Steril.*
848 2018;109(5):888-899. doi:10.1016/j.fertnstert.2018.01.038
 - 849 19. Balen A. Polycystic ovary syndrome. *InnovAiT.* 2016;9(3):144-150.
 - 850 20. Kumarendran B, Sumilo D, O'Reilly MW, et al. Increased risk of obstructive sleep
851 apnoea in women with polycystic ovary syndrome: a population-based cohort
852 study. *Eur J Endocrinol.* 2019;180(4):265-272. doi:10.1530/EJE-18-0693

-
- 853 21. Dokras A. Mood and anxiety disorders in women with PCOS. *Steroids*.
854 2012;77(4):338-341. doi:10.1016/j.steroids.2011.12.008
 - 855 22. Davari-Tanha F, Hosseini Rashidi B, Ghajarzadeh M, Noorbala AA. Bipolar
856 disorder in women with polycystic ovarian syndrome (PCO). *Acta Med Iran*.
857 2014;52(1):46-48.
 - 858 23. Kerchner A, Lester W, Stuart SP, Dokras A. Risk of depression and other mental
859 health disorders in women with polycystic ovary syndrome: a longitudinal
860 study. *Fertil Steril*. 2009;91(1):207-212. doi:10.1016/j.fertnstert.2007.11.022
 - 861 24. Farrell K, Antoni MH. Insulin resistance, obesity, inflammation, and depression in
862 polycystic ovary syndrome: biobehavioral mechanisms and interventions.
863 *Fertil Steril*. 2010;94(5):1565-1574. doi:10.1016/j.fertnstert.2010.03.081
 - 864 25. Hollinrake E, Abreu A, Maifeld M, Van Voorhis BJ, Dokras A. Increased risk of
865 depressive disorders in women with polycystic ovary syndrome. *Fertil Steril*.
866 2007;87(6):1369-1376. doi:10.1016/j.fertnstert.2006.11.039
 - 867 26. Yin X, Ji Y, Chan CLW, Chan CHY. The mental health of women with polycystic
868 ovary syndrome: a systematic review and meta-analysis. *Arch Womens Ment*
869 *Health*. 2021;24(1):11-27. doi:10.1007/s00737-020-01043-x
 - 870 27. Prince M, Patel V, Saxena S, et al. No health without mental health. *Lancet*.
871 2007;370(9590):859-877. doi:10.1016/S0140-6736(07)61238-0
 - 872 28. Memon A, Taylor K, Mohebati LM, et al. Perceived barriers to accessing mental
873 health services among black and minority ethnic (BME) communities: a
874 qualitative study in Southeast England. *BMJ Open*. 2016;6:e012337.
875 doi:10.1136/bmjopen-2016-012337
 - 876 29. American Psychiatric Association. *Diagnostic and statistical manual of mental*
877 *disorders*. 5th ed. 2013:21.

-
- 878 30. Spitzer RL, Kroenke K, Williams JB. Validation and utility of a self-report version
879 of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of
880 Mental Disorders. Patient Health Questionnaire. *JAMA*. 1999;282(18):1737-
881 1744. doi:10.1001/jama.282.18.1737
- 882 31. Snaith RP, Zigmond AS. The hospital anxiety and depression scale. *Br Med J*
883 (*Clin Res Ed*). 1986;292(6516):344. doi:10.1136/bmj.292.6516.344
- 884 32. Beck AT, Steer RA, Brown GK. *Beck depression inventory (BDI-II)*. Pearson;
885 1996.
- 886 33. Davidson J, Turnbull CD, Strickland R, et al. The Montgomery - Åsberg
887 Depression Scale: reliability and validity. *Acta Psychiatr Scand*.
888 1986;73(5):544-548. doi:10.1111/j.1600-0447.1986.tb02723.x
- 889 34. Devins GM, Orme CM, Costello CG, et al. Measuring depressive symptoms in
890 illness populations: Psychometric properties of the Center for Epidemiologic
891 Studies Depression (CES-D) scale. *Psychology and Health*. 1988;2(2):139-
892 156. doi:10.1080/08870448808400349
- 893 35. Score IRC. The Reynolds Adolescent Depression Scale-(RADS-2).
894 *Comprehensive Handbook of Psychological Assessment, Volume 2:*
895 *Personality Assessment*. 2003;2:224.
- 896 36. REFERENCE MISSING
- 897 37. REFERENCE MISSING
- 898 38. Spitzer RL, Kroenke K, Williams JB, et al. A brief measure for assessing
899 generalized anxiety disorder: the GAD-7. *Arch Intern Med*. 2006;166(10):1092-
900 1097. doi:10.1001/archinte.166.10.1092
- 901 39. REFERENCE MISSING

-
- 902 40. Cinar N, Harmanci A, Demir B, et al. Effect of an oral contraceptive on emotional
903 distress, anxiety and depression of women with polycystic ovary syndrome: a
904 prospective study. *Hum Reprod.* 2012;27(6):1840-1845.
905 doi:10.1093/humrep/des113
- 906 41. Benson J, Severn C, Hudnut-Beumler J, et al. Depression in Girls With Obesity
907 and Polycystic Ovary Syndrome and/or Type 2 Diabetes. *Can J Diabetes.*
908 2020;44(6):507-513. doi:10.1016/j.jcjd.2020.05.015
- 909 42. Pastore LM, Patrie JT, Morris WL, et al. Depression symptoms and body
910 dissatisfaction association among polycystic ovary syndrome women. *J*
911 *Psychosom Res.* 2011;71(4):270-276. doi:10.1016/j.jpsychores.2011.02.005
- 912 43. Maya J, Siegel J, Cheng TQ, et al. Prevalence and risk factors of polycystic
913 ovarian syndrome among an ethnically diverse overweight/obese adolescent
914 population. *Int J Adolesc Med Health.* 2020. doi:10.1515/ijamh-2019-0109
- 915 44. Rodrigues CE, Ferreira Lde L, Jansen K, et al. Evaluation of common mental
916 disorders in women with polycystic ovary syndrome and its relationship with
917 body mass index. *Rev Bras Ginecol Obstet.* 2012;34(10):442-446.
918 doi:10.1590/s0100-72032012001000002
- 919 45. DerSimonian R, Laird N. Meta-analysis in clinical trials. *Controlled clinical trials.*
920 1986;7(3):177-188. doi:10.1016/0197-2456(86)90046-2
- 921 46. Newcombe RG. Interval estimation for the difference between independent
922 proportions: comparison of eleven methods. *Statistics in medicine.*
923 1998;17(8):873-890. doi:10.1002/(sici)1097-0258(19980430)17:8<873::aid-
924 sim779>3.0.co;2-i

-
- 925 47. Newcombe RG. Two - sided confidence intervals for the single proportion:
 926 comparison of seven methods. *Statistics in medicine*. 1998;17(8):857-872.
 927 doi:10.1002/(sici)1097-0258(19980430)17:8<857::aid-sim777>3.0.co;2-e
- 928 48. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-
 929 analyses. *Bmj* 2003;327(7414):557-560. doi:10.1136/bmj.327.7414.557
- 930 49. REFERENCE MISSING
- 931 50. REFERENCE MISSING
- 932 51. REFERENCE MISSING
- 933 52. REFERENCE MISSING
- 934 53. REFERENCE MISISNG
- 935 54. REFERENCE MISSING
- 936 55. REFERENCE MISSING
- 937 56. Hoeger KM, Dokras A, Piltonen T. Update on PCOS: Consequences,
 938 Challenges, and Guiding Treatment. *J Clin Endocrinol Metab*.
 939 2021;106(3):e1071-e1083. doi:10.1210/clinem/dgaa839
- 940 57. Witchel SF, Teede HJ, Peña AS. Curtailing PCOS. *Pediatr Res*. 2020;87(2):353-
 941 361. doi:10.1038/s41390-019-0615-1
- 942 58. Lin AW, Bergomi EJ, Dollahite JS, Sobal J, Hoeger KM, Lujan ME. Trust in
 943 Physicians and Medical Experience Beliefs Differ Between Women With and
 944 Without Polycystic Ovary Syndrome. *J Endocr Soc*. 2018;2(9):1001-1009.
 945 doi:10.1210/js.2018-00181
- 946 59. Hillman SC, Bryce C, Caleyachetty R, Dale J. Women's experiences of
 947 diagnosis and management of polycystic ovary syndrome: a mixed-methods
 948 study in general practice. *Br J Gen Pract*. 2020;70(694):e322-e329.
 949 doi:10.3399/bjgp20X708881

-
- 950 60. Saidunnisa BG, Shariff A, Ayman G, Mohammad B, Housam R, Khaled N.
 951 Assessment of Risk Factors for development of Polycystic Ovarian Syndrome.
 952 *Int J Contemp Med Research*. 2017;4(1):164-167.
- 953 61. Lo JC, Feigenbaum SL, Yang J, Pressman AR, Selby JV, Go AS. Epidemiology
 954 and Adverse Cardiovascular Risk Profile of Diagnosed Polycystic Ovary
 955 Syndrome. *J Clin Endocrinol Metab*. 2006;91(4):1357-1363.
 956 doi:10.1210/jc.2005-2430
- 957 62. Cooney LG, Dokras A. (2018) Beyond fertility: polycystic ovary syndrome and
 958 long-term health. *Fertil Steril*. 2018;110(5):794-809.
 959 doi:10.1016/j.fertnstert.2018.08.021
- 960 63. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The
 961 prevalence and features of the polycystic ovary syndrome in an unselected
 962 population. *J Clin Endocrinol Metab*. 2004;89(6):2745-2749.
 963 doi:10.1210/jc.2003-032046
- 964 64. McManus S, Bebbington P, Jenkins R, Brugha T, eds. *Mental health and*
 965 *wellbeing in England: Adult Psychiatric Morbidity Survey 2014*. NHS Digital;
 966 2016.
- 967 65. Gajwani R, Parsons H, Birchwood M, Singh SP. Ethnicity and detention: are
 968 Black and minority ethnic (BME) groups disproportionately detained under the
 969 Mental Health Act 2007?. *Soc Psychiatry Psychiatr Epidemiol*.
 970 2016;51(5):703-711. doi:10.1007/s00127-016-1181-z
- 971 66. Linney C, Ye S, Redwood S, et al. "Crazy person is crazy person. It doesn't
 972 differentiate": an exploration into Somali views of mental health and access to

-
- 973 healthcare in an established UK Somali community. *Int J Equity Health*.
 974 2020;19(1):190. doi:10.1186/s12939-020-01295-0
- 975 67. Ledger WL, Atkin SL, Sathyapalan T. *Long-term Consequences of Polycystic*
 976 *Ovary Syndrome: Green-top Guideline No. 33*. 3rd ed. Royal College of
 977 Obstetricians and Gynaecologists; 2014.
 978 https://www.rcog.org.uk/globalassets/documents/guidelines/gtg_33.pdf
- 979 68. Greenwood EA, Yaffe K, Wellons MF, Cedars MI, Huddleston HG. Depression
 980 over the lifespan in a population-based cohort of women with polycystic ovary
 981 syndrome: longitudinal analysis. *J Clin Endocrinol Metab*. 2019;104(7):2809-
 982 2819. doi:10.1210/jc.2019-00234
- 983 69. Cooney LG, Dokras A. Depression and Anxiety in Polycystic Ovary Syndrome:
 984 Etiology and Treatment. *Curr Psychiatry Rep*. 2017;19(11):83.
 985 doi:10.1007/s11920-017-0834-2
- 986 70. Craske MG, Stein MB. Anxiety. *Lancet*. 2016;388(10063):3048-3059.
 987 doi:10.1016/S0140-6736(16)30381-6
- 988 **71. REFERENCE MISSING**
- 989 72. Galmiche M, Déchelotte P, Lambert G, Tavalacci MP. Prevalence of eating
 990 disorders over the 2000-2018 period: a systematic literature review. *Am J Clin*
 991 *Nutr*. 2019;109(5):1402-1413. doi:10.1093/ajcn/nqy342
- 992 73. Tay CT, Teede HJ, Hill B, Loxton D, Joham AE. Increased prevalence of eating
 993 disorders, low self-esteem, and psychological distress in women with
 994 polycystic ovary syndrome: a community-based cohort study. *Fertil Steril*.
 995 2019;112(2):353-361. doi:10.1016/j.fertnstert.2019.03.027

-
- 996 74. Greenwood EA, Pasch LA, Cedars MI, Huddleston HG. Obesity and depression
997 are risk factors for future eating disorder-related attitudes and behaviors in
998 women with polycystic ovary syndrome. *Fertil Steril*. 2020;113(5):1039-1049.
999 doi:10.1016/j.fertnstert.2020.01.016
- 1000 75. Lee I, Cooney LG, Saini S, et al. Increased risk of disordered eating in polycystic
1001 ovary syndrome. *Fertil Steril*. 2017;107(3):796-802.
1002 doi:10.1016/j.fertnstert.2016.12.014
- 1003 76. Cesta CE, Månsson M, Palm C, Lichtenstein P, Iliadou AN, Landén M. Polycystic
1004 ovary syndrome and psychiatric disorders: Co-morbidity and heritability in a
1005 nationwide Swedish cohort. *Psychoneuroendocrinology*. 2016;73:196-203.
1006 doi:10.1016/j.psyneuen.2016.08.005
- 1007 77. Qassem T, Bebbington P, Spiers N, McManus S, Jenkins R, Dein S. Prevalence
1008 of psychosis in black ethnic minorities in Britain: analysis based on three
1009 national surveys. *Soc Psychiatry Psychiatr Epidemiol*. 2015;50(7):1057-1064.
1010 doi:10.1007/s00127-014-0960-7
- 1011 78. Hung JH, Hu LY, Tsai SJ, et al. Risk of psychiatric disorders following polycystic
1012 ovary syndrome: a nationwide population-based cohort study. *PLoS One*.
1013 2014;9(5):e97041. doi:10.1371/journal.pone.0097041
- 1014 79. Brutocao C, Zaiem F, Alsawas M, Morrow AS, Murad MH, Javed A. Psychiatric
1015 disorders in women with polycystic ovary syndrome: a systematic review and
1016 meta-analysis. *Endocrine*. 2018;62(2):318-325. doi:10.1007/s12020-018-
1017 1692-3

-
- 1018 80. Grunze H. Chapter 40 - Bipolar Disorder. In: Zigmond MJ, Rowland LP, Coyle
 1019 JT, eds. *Neurobiology of Brain Disorders*. Academic Press, San Diego;
 1020 2015:655-673.
- 1021 81. Rasgon NL, Altshuler LL, Fairbanks L, et al. Reproductive function and risk for
 1022 PCOS in women treated for bipolar disorder. *Bipolar Disord*. 2005;7(3):246-
 1023 259. doi:10.1111/j.1399-5618.2005.00201.x
- 1024 82. Hussain A, Chandel RK, Ganie MA, et al. Prevalence of psychiatric disorders in
 1025 patients with a diagnosis of polycystic ovary syndrome in kashmir. *Indian J*
 1026 *Psychol Med*. 2015;37(1):66-70. doi:10.4103/0253-7176.150822
- 1027 83. REFERENCE MISSING
- 1028 84. REFERENCE MISSING
- 1029 85. REFERENCE MISSING
- 1030 86. REFERENCE MISSING
- 1031 87. Casey, M. Health Needs Assessment of the Nepali Community in Rushmoor.
 1032 Hampshire County Council. Updated October, 2010.
 1033 <https://documents.hants.gov.uk/public-health/NepaliHealthNeedsAssessment2010.pdf>
- 1034 88. Cooper C, Spiers N, Livingston G, et al. Ethnic inequalities in the use of health
 1035 services for common mental disorders in England. *Soc Psychiatry Psychiatr*
 1036 *Epidemiol*. 2013;48(5):685-692. doi:10.1007/s00127-012-0565-y
- 1037 89. Simkhada B, Vahdaninia M, van Teijlingen E, Blunt H. Cultural issues on
 1038 accessing mental health services in Nepali and Iranian migrants communities in the
 1039 UK. *Int J Ment Health Nurs*. 2021. doi:10.1111/inm.12913

1040
1041
1042
1043
1044
1045